Colon Cancer, Rectal Cancer
Conditions
Keywords
bevacizumab, proteinuria
Brief summary
This is a clinical research study to look at the incidence of proteinuria (a condition in which urine contains an abnormal amount of protein) caused by shortened infusions (given into the vein over 10 or 15 minutes) of bevacizumab (a medication prescribed for colon, lung, or breast cancer). There are currently no published studies or clinical data looking at how safe shortened infusions of bevacizumab are in relationship to the side effect of proteinuria. We hypothesis that shortened infusions of bevacizumab will result in an increased risk for proteinuria compared to the standard infusions of this agent.
Interventions
None listed
Sponsors
University of Texas Southwestern Medical Center
North Texas Veterans Healthcare System
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must be 18 years older * Patients must be receiving his/her first dose of bevacizumab * Patients must sign an informed consent
Exclusion criteria
* Patients receiving \> 10 mg/kg doses of bevacizumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of shortened infusions (0.5 mg/kg/min) of bevacizumab on the incidence of proteinuria. | 3-6 months |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the time (number of days) to the incidence of proteinuria with shortened infusions of bevacizumab AND to evaluate the effect of controlled versus uncontrolled hypertension and the incidence of proteinuria. | 3-6 months |
Countries
United States
Outcome results
None listed